An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Docetaxel and Cisplatin Every 3 Weeks in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2011
At a glance
- Drugs Cisplatin; Docetaxel; Ombrabulin
- Indications Lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Jul 2011 Planned end date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.